Quantcast

Latest Genentech Inc. Stories

2010-07-11 18:00:00

LONDON, July 12, 2010 /PRNewswire/ -- MRC Technology (UK) announced today that it has entered into an agreement with Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for an exclusive licence to a series of small molecule drug candidates for the potential treatment of neurological disease. This is the first small molecule chemistry programme to come out of MRC Technology's Centre for Therapeutics Discovery (CTD) and the first major small molecule...

2009-09-10 07:46:00

NEW YORK, Sept. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. World Cancer Therapies Market http://www.reportlinker.com/p0109886/World-Cancer-Therapies-Market.html This report analyzes the global market for Cancer Therapies in US$ Billion. The specific product segments analyzed are Chemotherapy, Targeted Therapy, Hormonal Therapy, and Immunotherapy. Annual forecasts for the global market is provided for the period of 2006...

2009-09-08 09:07:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Small Molecule Kinase Inhibitors http://www.reportlinker.com/p0131227/Small-Molecule-Kinase-Inhibitors.html This report analyzes the Global Market for Small Molecule Kinase Inhibitors in Millions of US$ by the following Product Segments: Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, Tykerb/Tyverb, and Others. Annual forecasts are provided for the...

2009-06-29 00:00:00

RICHMOND, Calif., June 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that a key research milestone has been achieved in its Research and License Agreement with Genentech, Inc., a wholly-owned member of the Roche Group, for the generation of cell lines with novel characteristics for pharmaceutical protein production purposes using Sangamo's proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. Genentech scientists demonstrated the...

2009-06-15 06:00:00

VANCOUVER, June 15 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced that twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study were presented on June 14, 2009 during the 17th Congress of the European Society of Ophthalmology in Amsterdam, the Netherlands. MONT BLANC is the European study of the Novartis sponsored SUMMIT clinical trial program which investigates the efficacy and safety of combining Visudyne(R) (Novartis Pharma AG)...

2009-04-09 07:39:23

The U.S. Food and Drug Administration says Genentech Inc. is withdrawing the psoriasis drug Raptiva and it will no longer be available in the United States. The FDA said the company is taking the action because of a potential risk of patients developing progressive multifocal leukoencephalopathy -- a rare, serious, progressive neurologic disease caused by a virus that affects the central nervous system. FDA officials said prescribers are being asked not to initiate new Raptiva (efalizumab)...

2009-04-08 10:01:00

CHICAGO, April 8 /PRNewswire/ -- "Options News," hosted by Carrie Long and www.ONN.tv Senior Market Specialist Jared Levy, reviews futures and overseas trading, discusses the latest economic news, and analyzes notable options activity. (Logo: http://www.newscom.com/cgi-bin/prnh/20090323/AQM046LOGO) Today's program dissects Alcoa's (AA) earnings report, which unofficially kicked off earnings season Tuesday night. Jared and Carrie also look at the CBOE SPX Volatility Index (VIX) and analyze...

08a3790c70debdbc9529e7d40684f7211
2009-02-05 10:45:34

An approach that involves mixing two drugs to battle advanced cases of colon cancer appears to make the condition worse, a new study finds. Early lab tests and a small study had shown that advanced forms of colon cancer could be effectively fought using a combination of Eli Lilly & Co.'s Erbitux and Genentech Inc.'s Avastin because both drugs are designed to target the cancer in different ways. However, study leader Dr. Cornelis Punt and colleagues found evidence to suggest that the...

2008-12-30 12:29:00

WASHINGTON, Dec. 30 /PRNewswire-USNewswire/ -- The Coalition for 21st Century Medicine strongly opposes the citizen petition filed by Genentech, Inc. on December 5, 2008, seeking to restrict the ability of laboratories to offer diagnostic tests to physicians and patients. The request threatens innovation in laboratory tests, would harm patient care and rests on flawed scientific and legal premises. The Coalition's mission is to encourage the research, development, and commercialization of...

db58bd74ead6bf10fabe00ebacef04991
2008-12-22 07:55:00

The next big step in satisfying the computing needs of businesses may come from so-called "cloud computing." Cloud computing allows a group to use the IT-related capabilities via the Internet without having to control the technology infrastructure that supports them. While once it was considered to be a distant concept, cloud computing has become a more feasible option for businesses. Cloud computing has already hit an estimated $36 billion market this year, representing roughly 13 percent...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related